Optimization of 2-piperidin-4-yl-acetamides as melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Designing out hERG inhibition |
| |
| Authors: | Susanne Berglund Bryan J Egner Henrik Gradén Joakim Gradén David GA Morgan Tord Inghardt Fabrizio Giordanetto |
| |
| Institution: | 1. Medicinal Chemistry, AstraZeneca R&D Mölndal, Pepparedsleden 1, SE-431 83, Mölndal, Sweden;2. CVGI Bioscience, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire SK104TG, UK;3. Lead Generation, AstraZeneca R&D Mölndal, Pepparedsleden 1, SE-431 83, Mölndal, Sweden |
| |
| Abstract: | Herein, we disclose the discovery and optimization of 2-piperidin-4-yl-acetamide derivatives as MCH-R1 antagonists. Structural investigation of piperidin-4-yl-amide and piperidin-4-yl-ureas identified 2-piperidin-4-yl-acetamide-based MCH-R1 antagonists with outstanding in vivo efficacy but flawed with high affinity towards the hERG potassium channel. While existing hERG SAR information was employed to discover highly potent MCH-R1 antagonists with minimized hERG inhibition, additional hurdles prevented their subsequent clinical exploration. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
